Table 1.
Summary of efficacy in clinical trials of lenvatinib in the treatment of thyroid cancer
| Study [ref] | Arm | Subtype | N | PFS, months (95% CI) |
OS, months (95% CI) |
ORR (%) |
DCR (%) |
|---|---|---|---|---|---|---|---|
| Phase II [8] | Lenvatinib | DTC | 58 | 12.6 (9.9–16.1) | - | 50 | 93 |
| Phase II [9] | Lenvatinib | MTC | 59 | 9.0 (7.0-NE) | - | 36 | 80 |
| Phase II (Japan) [10] | Lenvatinib | DTC | 25 | 25.8 (18.4–NE) | 31.8 (31.8–NE) | 68 | 100 |
| MTC | 9 | 9.2 (1.8–NE) | 12.1 (3.8–NE) | 22 | 100 | ||
| ATC | 17 | 7.4 (1.7–12.9) | 10.6 (3.8–19.8) | 24 | 94 | ||
| Phase III (general population) [2] | Lenvatinib | DTC | 261 | 18.3 (15.1–NE) | NE | 64.8 | 87.7 |
| Placebo | 131 | 3.6 (2.2–3.7) | 1.5 | 55.7 | |||
| Phase III (Japanese population) [7] | Lenvatinib | DTC | 30 | 16.5 (7.4-NE) | NE | 63.3 | 90.0 |
| Placebo | 10 | 3.7 (1.6–9.1) | 0.0 | 60.0 |
ATC anaplastic thyroid cancer; DCR disease control rate; DTC differentiated thyroid cancer; MTC medullary thyroid cancer; NE, not estimable; ORR overall response rate; OS overall survival; PFS progression-free survival